Actively Recruiting
Robotic Transjugular Transcatheter Tricuspid Valve Replacement
Led by Prince of Wales Hospital, Shatin, Hong Kong · Updated on 2026-04-07
10
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
Sponsors
P
Prince of Wales Hospital, Shatin, Hong Kong
Lead Sponsor
J
Jenscare Scientific
Collaborating Sponsor
AI-Summary
What this Trial Is About
Valvular heart disease (VHD), caused by abnormalities in heart valves, can lead to severe complications such as heart failure and death, with approximately 220 million affected patients worldwide. The prevalence of VHD continues to grow alongside the aging global population. Transcatheter heart valve interventions have emerged as minimally invasive alternatives, offering benefits like shorter recovery times and reduced discomfort. However, current manual catheter-based techniques are complex, highly dependent on clinicians' expertise, and involve significant physical risk due to prolonged exposure to X-ray radiation and cumbersome protective gear. To address these challenges, a novel, universal intracardiac robotic system is proposed to improve precision, safety, and procedural efficiency. This system integrates a high-dexterity, load-capacity catheter instrument, a modular concentric robotic platform, and an augmented reality (AR) navigation interface. The catheter's design balances flexibility for navigating complex intracardiac paths with the rigidity needed for device deployment. The robotic platform's modular architecture enhances versatility, enabling control across various procedures and anatomical variations, while the AR system facilitates intuitive preoperative planning and real-time intraoperative guidance through multimodal image fusion. The core innovation lies in overcoming existing limitations: balancing catheter flexibility and load capacity, expanding robotic system adaptability for different valve procedures, and improving integration with imaging modalities like computed tomography, transesophageal echocardiogram, and fluoroscopy. The project aims to develop sophisticated models for instrument design, control strategies for multi-instrument coordination, and advanced navigation tools. These technological advancements are intended to elevate the clinical utility of robotic intracardiac interventions, making them safer, more efficient, and easier to adopt widely. By establishing a systematic approach for intelligent, multimodal, robotic-assisted valvular procedures, this work promises significant contributions to minimally invasive cardiology and holds substantial potential for clinical translation.
CONDITIONS
Official Title
Robotic Transjugular Transcatheter Tricuspid Valve Replacement
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 18 and 90 years
- Severe symptomatic tricuspid regurgitation
- High risk for tricuspid valve surgery as determined by a multidisciplinary heart team
- Anatomically suitable for transjugular transcatheter tricuspid valve replacement using the Lux Valve Plus system
- Able to give informed consent
You will not qualify if you...
- Previous tricuspid valve repair or replacement interfering with Lux Valve Plus implantation
- Severe pulmonary hypertension (pulmonary artery systolic pressure >70 mm Hg or >2/3 systemic with pulmonary vascular resistance >5 WU after vasodilator challenge)
- Pregnant, nursing, or planning pregnancy during the study; females of childbearing potential must have a negative pregnancy test
- Left ventricular ejection fraction less than 40%
- Presence of intracardiac mass, thrombus, or vegetation
- Anatomical issues preventing proper device deployment or vascular access
- Surgical correction required for other severe valvular diseases; must wait 2 months after treatment before reassessment
- Sepsis or active endocarditis within 3 months, or infections needing antibiotics within 2 weeks prior to procedure
- Active peptic ulcer or gastrointestinal bleeding preventing anticoagulation or antiplatelet therapy
- Cardiac or non-cardiac surgery or intervention within 30 days before or planned within 60 days after valve procedure
- Recent stroke, transient ischemic attack, or myocardial infarction within 90 days before procedure
- Life expectancy less than 1 year
- Current participation in another investigational drug or device study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Prince of Wales Hospital
Shatin, Hong Kong
Actively Recruiting
Research Team
D
Daniel Xu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here